{"id":3304,"count":40,"description":"Modern\u00ed antiretrovirov\u00e1 terapie (ART) zm\u011bnila HIV z fat\u00e1ln\u00ed diagn\u00f3zy na zvl\u00e1dnuteln\u00fd chronick\u00fd stav \u2014 p\u0159i d\u016fsledn\u00e9 l\u00e9\u010db\u011b se d\u00e9lka \u017eivota bl\u00ed\u017e\u00ed norm\u00e1lu a virov\u00e1 suprese \u010din\u00ed sexu\u00e1ln\u00ed p\u0159enos prakticky nulov\u00fdm (U=U: nedetekovateln\u00e9 rovn\u00e1 se nep\u0159enosn\u00e9). Katalog HIV l\u00e9k\u016f MedsBase obsahuje hlavn\u00ed NRTI kostry, inhibitory integr\u00e1zy, tablety s kompletn\u00edm re\u017eimem a vybran\u00e9 dopl\u0148ky pou\u017e\u00edvan\u00e9 v modern\u00ed l\u00e9\u010db\u011b HIV a PrEP. V\u0161echny produkty jsou dod\u00e1v\u00e1ny spole\u010dnost\u00ed <strong>WHO-GMP certifikovan\u00fdch v\u00fdrobc\u016f<\/strong>.\n\n<strong>NRTI kostra \u2014 z\u00e1klad ART a PrEP.<\/strong> Tenofovir disoproxil fumar\u00e1t + emtricitabin (TDF\/FTC) je glob\u00e1ln\u011b nejpou\u017e\u00edvan\u011bj\u0161\u00ed NRTI kostra \u2014 pou\u017e\u00edv\u00e1 se jak jako sou\u010d\u00e1st l\u00e9\u010debn\u00fdch re\u017eim\u016f HIV, tak jako denn\u00ed profylaxe p\u0159ed expozic\u00ed (PrEP). Nab\u00edz\u00edme <a href=\"https:\/\/medsbase.com\/cs\/tenof-em\/\">Tenof EM<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/ricovir-em\/\">Ricovir EM<\/a>. Tenofovir alafenamid + emtricitabin (TAF\/FTC) \u2014 nov\u011bj\u0161\u00ed prol\u00e9\u010divo s lep\u0161\u00edm profilem bezpe\u010dnosti pro ledviny a kosti \u2014 je k dispozici jako <a href=\"https:\/\/medsbase.com\/cs\/tavin-em\/\">Tavin EM<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/tenvir-af\/\">Tenvir AF<\/a>. Lamivudinov\u00e1 monoterapie (3TC, z\u00e1kladn\u00ed NRTI pro kombinovanou l\u00e9\u010dbu HBV a vybran\u00e9 pediatrick\u00e9 protokoly) jako <a href=\"https:\/\/medsbase.com\/cs\/lamivir\/\">Lamivir<\/a>. Prohl\u00e9dn\u011bte si n\u00e1\u0161 <a href=\"https:\/\/medsbase.com\/cs\/prep-medication-pre-exposure-prophylaxis\/\">PrEP l\u00e9ky<\/a> kategorie pro kompletn\u00ed \u0159adu form\u00e1tovanou pro PrEP a n\u00e1\u0161 pr\u016fvodce <a href=\"https:\/\/medsbase.com\/cs\/what-is-hiv-prep-and-how-does-it-work\/\">Nejlep\u0161\u00ed PrEP l\u00e9ky 2026<\/a>.\n\n<strong>Inhibitory integr\u00e1zy (INSTI).<\/strong> Modern\u00ed prvn\u00ed linie ART kombinuje z\u00e1klad NRTI s inhibitorem integr\u00e1zy (dolutegravir, bictegravir nebo raltegravir) \u2014 vysok\u00e1 bari\u00e9ra v\u016f\u010di rezistenci, m\u00e9n\u011b l\u00e9kov\u00fdch interakc\u00ed a v\u00fdborn\u00e1 sn\u00e1\u0161enlivost. Raltegravir 400 mg je skladov\u00e1n jako <a href=\"https:\/\/medsbase.com\/cs\/ralmac-400\/\">Ralmac 400<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/instgra\/\">Instgra<\/a>.\n\n<strong>Kompletn\u00ed re\u017eimy v jedn\u00e9 tablet\u011b (STR).<\/strong> Jednotabletov\u00e9 jednodenn\u00ed re\u017eimy zjednodu\u0161uj\u00ed ART a zlep\u0161uj\u00ed adherenci. <a href=\"https:\/\/medsbase.com\/cs\/avonza\/\">Avonza<\/a> kombinuje tenofovir + lamivudin + efavirenz (TLE \u2014 prvn\u00ed linie WHO po mnoho let a st\u00e1le \u0161iroce pou\u017e\u00edvan\u00fd v prost\u0159ed\u00edch s omezen\u00fdmi zdroji). <a href=\"https:\/\/medsbase.com\/cs\/teravir\/\">Teravir<\/a> poskytuje tenofovir + lamivudin. <a href=\"https:\/\/medsbase.com\/cs\/taficita\/\">Taficita<\/a> obsahuje TAF + emtricitabin + inhibitor integr\u00e1zy t\u0159\u00eddy bictegravir, modern\u00ed preferovan\u00fd re\u017eim prvn\u00ed linie.\n\n<strong>Dal\u0161\u00ed NRTI a dopl\u0148ky.<\/strong> Kombinace lamivudinu a zidovudinu (AZT\/3TC) je skladov\u00e1na jako <a href=\"https:\/\/medsbase.com\/cs\/hivus-lr\/\">Hivus-LR<\/a>. Kombinace inhibitor\u016f prote\u00e1zy s ritonavirem jako <a href=\"https:\/\/medsbase.com\/cs\/ritocom\/\">Ritocom<\/a>. Vybran\u00e9 star\u0161\u00ed re\u017eimy v\u010detn\u011b <a href=\"https:\/\/medsbase.com\/cs\/trioday\/\">Trioday<\/a> z\u016fst\u00e1vaj\u00ed katalogizov\u00e1ny pro p\u0159echod\/pokra\u010dovac\u00ed pou\u017eit\u00ed.\n\n<strong>Jak vybrat \u2014 a d\u016fle\u017eit\u00e1 upozorn\u011bn\u00ed.<\/strong> Modern\u00ed doporu\u010den\u00ed WHO a DHHS pro prvn\u00ed linii je dolutegravir nebo bictegravir + TAF\/FTC (nebo TDF\/FTC, kde nen\u00ed TAF dostupn\u00fd). P\u0159echod ze star\u0161\u00edch re\u017eim\u016f (na b\u00e1zi efavirenzu, na b\u00e1zi AZT) je vhodn\u00fd pro v\u011bt\u0161inu pacient\u016f, ale m\u011bl by b\u00fdt proveden v koordinovan\u00e9m prost\u0159ed\u00ed p\u00e9\u010de o HIV. PrEP vy\u017eaduje z\u00e1kladn\u00ed testov\u00e1n\u00ed na HIV (negativn\u00ed stav) a \u010dtvrtletn\u00ed p\u0159etestov\u00e1n\u00ed \u2014 to je z\u00e1sadn\u00ed pro zabr\u00e1n\u011bn\u00ed vzniku rezistence na integ\u00e1zu u nediagnostikovan\u00e9 akutn\u00ed HIV. Spole\u010dn\u00e9 testov\u00e1n\u00ed na pohlavn\u011b p\u0159enosn\u00e9 infekce, stav hepatitidy B, funkce ledvin a hodnocen\u00ed hustoty kost\u00ed jsou sou\u010d\u00e1st\u00ed standardn\u00ed p\u00e9\u010de o HIV\/PrEP.\n\n<strong>Kritick\u00e9.<\/strong> Nez\u00edsk\u00e1vejte l\u00e9ky na HIV bez pr\u016fb\u011b\u017en\u00e9 spolupr\u00e1ce s poskytovatelem p\u00e9\u010de o HIV \u2013 monitorov\u00e1n\u00ed adherence, sledov\u00e1n\u00ed virov\u00e9 n\u00e1lo\u017ee, monitorov\u00e1n\u00ed CD4, kontrola interakc\u00ed l\u00e9k\u016f a testov\u00e1n\u00ed rezistence jsou nezbytn\u00e9 pro dlouhodobou bezpe\u010dnost a \u00fa\u010dinnost. U koinfekce hepatitidou B je nutn\u00e1 pe\u010dliv\u00e1 volba re\u017eimu (TDF\/FTC a TAF\/FTC tak\u00e9 l\u00e9\u010d\u00ed HBV; n\u00e1hl\u00e9 ukon\u010den\u00ed m\u016f\u017ee zp\u016fsobit z\u00e1va\u017en\u00e9 vzplanut\u00ed HBV). T\u011bhotenstv\u00ed: v\u011bt\u0161ina modern\u00edch re\u017eim\u016f je bezpe\u010dn\u00e1; inhibitory integr\u00e1zy jsou st\u00e1le v\u00edce preferov\u00e1ny.\n\nV\u0161echny produkty HIV Medication od MedsBase jsou odes\u00edl\u00e1ny z <strong>WHO-GMP certifikovan\u00fdch v\u00fdrobc\u016f<\/strong> s diskr\u00e9tn\u00edm balen\u00edm a jsou kryty na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.\n\n<!-- mb-hub-link --><strong>N\u00e1kupn\u00ed pr\u016fvodce 2026:<\/strong> Prohl\u00e9dn\u011bte si n\u00e1\u0161 v\u00fdb\u011br <a href=\"\/cs\/best-hiv-treatment-regimens-2026\/\">Nejlep\u0161\u00ed l\u00e9\u010debn\u00e9 re\u017eimy HIV 2026<\/a> pro se\u0159azen\u00e9 tipy, srovn\u00e1vac\u00ed tabulku, d\u00e1vkov\u00e1n\u00ed a zkratku k rozhodnut\u00ed.","link":"https:\/\/medsbase.com\/cs\/hiv-medication\/","name":"L\u00e9ky na HIV","slug":"hiv-medication","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product?product_cat=3304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}